Top 300 Pharmacy Drug Cards


Class: Oral Contraceptive

Product Contents: Oral Contraceptive—Triphasic



Dosage Forms. Tablet: Triphasic products contain three sets of tablets, each phase containing a combination of varying doses of estrogen/progestin agents; products are either in 21-d or in 28-d cycles; may also include inert tablets containing either plain lactose or iron supplements, generally as 75-mg ferrous fumarate

Common FDA Label Indication, Dosing, and Titration.

1. Contraception: 1 tablet po daily beginning either on the first Sunday after menstruation begins (“Sunday start”) or on the first day of menstruation (“day 1 start”); tablets are taken sequentially, following the arrows marked on the dispenser

2. Acne vulgaris, moderate: In females at least 15 y of age who have achieved menarche, and are unresponsive to topical antiacne medications; same dosing as for contraception (Ortho Tri-Cyclen and Estrostep Fe are the only products with this FDA-approved indication)

Off-Label Uses. None

MOA. See Preface C Card: General Content Related to All Oral Contraceptives.

Drug Characteristics: Oral Contraceptive—Triphasica


aSee Preface C Card: General Content Related to All Oral Contraceptives for ADME data on progestins.

Medication Safety Issues: Oral Contraceptive—Triphasic


Drug Interactions and Adverse Reactions: Oral Contraceptive—Triphasic. See Preface C Card: General Content Related to All Oral Contraceptives.

Efficacy Monitoring Parameters. Lack of pregnancy.

Toxicity Monitoring Parameters. Annual physical examination including cervical cytology (Pap smear) and breast exam.

Key Patient Counseling Points. See Preface C Card: General Content Related to All Oral Contraceptives.

Clinical Pearls. Patients should not smoke during therapy, as this increases the risk of serious cardiovascular side effects. Noncontraceptive benefits (non-FDA approved) of oral contraceptive use include treatment of dysmenorrhea; acne; menstrual migraine; pelvic pain due to endometriosis; and decreased risk of endometrial, ovarian and colorectal cancer. Multiphasic products have a lower total steroid dose than monophasic products and may have lower adverse effect rates, but treatment is usually initiated with monophasic products. Multiple nonoral hormonal contraceptive products also available.